Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27471846 | 0.98 | OXTR (0.38) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL24122595 | 0.80 | ITGB2 (0.43) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL18754637 | 0.80 | OXTR (0.37) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL3794975 | 0.80 | ABCG2 (0.50) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL236649 | 0.78 | OXTR (0.42) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL14182625 | 0.77 | OXTR (0.39) | OXTRMAOAMAOBABCG2 | |
| SCHEMBL7035762 | 0.76 | OXTR (0.34) | OXTRMAOAMAOB | |
| SCHEMBL28644317 | 0.75 | OXTR (0.39) | OXTRMAOAMAOBABCG2ITGB2 | |
| SCHEMBL11926948 | 0.75 | HTR1A (0.42) | — | |
| SCHEMBL5985680 | 0.75 | HTR2B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632906-B1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230350294-A1 | Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4257588-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | Reistone Biopharma Company Limited (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257584-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| US-11768434-B2 | Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-26 | — | — | US | disclosed |
| EP-4183774-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-4129345-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-114262250-A | Synthetic method of aromatic ring benzyl ortho-position dialkyl | 乐威医药（江苏）股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021249522-A1 | PYRIDONE-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2021-12-16 | — | — | WO | disclosed |
| US-8865716-B2 | Dihydropteridinones II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865716-B2 | Dihydropteridinones II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| WO-2014127816-A1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-28 | — | — | WO | disclosed |
| US-20130225593-A1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225593-A1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130196988-A1 | Dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196988-A1 | Dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| WO-2013020992-A1 | DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-14 | — | — | WO | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| CN-1212964-A | Sulfonic acid amide substituted benzodihydropyrane processes for their preparation, their use as medicament and pharmaceutical preparations comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196988-A1 | Dihydrothienopyrimidines | BACE1, BACE2, APP | OXTR 4323/4885MAOA 1885/4885MAOB 2067/4885 |
| US-20130225593-A1 | DIHYDROPTERIDINONES II | BACE1, BACE2, APP | OXTR 3763/4885MAOA 3151/4885MAOB 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.